Dr. Jose Tubio (Spain, 1978) is author of more than 10 papers in the high-impact journals Science, Nature and Nature Genetics. For the last years, he has carried out his research at the forefront of cancer genomics, being involved in the discovery of new cancer genes in haematological cancers and bone cancers, the identification of new mutational mechanisms in cancer development, the characterization of the evolutionary dynamics of metastasis, and the identification of mutational processes and genes that drive transmissible cancers. Noteworthy, the research he has carried out in the field of cancer retrotransposition is changing our understanding of the role that retrotransposons play in cancer. Currently, he is holder of an ERC Starting Grant, which aims the discovery of the genetic mechanisms that drive transmissible cancers.
Jose Tubio’s research focuses on the impact of structural variation in cancer development, and the genetic changes that make cancers contagious between individuals.
"The main focus of my research interests along my scientific career has been the impact of genomic structural variation (especially retrotransposition) on the function of eukaryotic genomes, and its role in disease (especially cancer). My research group is participating in the Pancancer Initiative of the International Cancer Genome Consortium (ICGC) and the Cancer Genome Atlas (TCGA), to investigate the mechanisms of coevolution between TEs and cancer. In addition, I am increasingly interested in the identification of drivers of cancer transmissibility in clonally transmissible cancers (i.e., cancers that are transmitted between individuals by direct transfer of living cancer cells)."
Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes.
Science (New York, N.Y.) 345 1251343 2014 Aug 1
PUBMED: 25082706; PMC: 4380235; DOI: 10.1126/science.1251343
Cancer: When catastrophe strikes a cell.
Nature 470 476-7 2011 Feb 24
PUBMED: 21350479; DOI: doi:10.1038/470476a
Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin.
Science (New York, N.Y.) 348 880-6 2015 May 22
PUBMED: 25999502; PMC: 4471149; DOI: 10.1126/science.aaa6806
The evolutionary history of lethal metastatic prostate cancer.
Nature 520 353-357 2015 Apr 16
PUBMED: 25830880; DOI: 10.1038/nature14347
Transmissible [corrected] dog cancer genome reveals the origin and history of an ancient cell lineage.
Science (New York, N.Y.) 343 437-440 2014 Jan 24
PUBMED: 24458646; PMC: 3918581; DOI: 10.1126/science.1247167
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.
Nature genetics 46 116-25 2014 Feb
PUBMED: 24413735; PMC: 3960636; DOI: 10.1038/ng.2874
Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma.
Nature genetics 45 923-6 2013 Aug
PUBMED: 23770606; PMC: 3743157; DOI: 10.1038/ng.2668
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
Nature 475 101-5 2011 Jun 5
PUBMED: 21642962; PMC: 3322590; DOI: 10.1038/nature10113
Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia.
Nature genetics 44 47-52 2011 Dec 11
PUBMED: 22158541; DOI: 10.1038/ng.1032